P12.01.B Systemic metabolic features associated with significant insulin resistance in diabetes mellitus type 2 patients are related to the presence of gemistocytes in glioblastoma

Abstract Background Gemistocytes (GCs) are unique phenotype of reactive astrocytes. In diffuse low-grade gliomas, they associated with grim prognosis. Less is known regarding their pathogenesis and prognostic significance in glioblastoma (GBM). Previous data on-neoplastic central nervous system (CNS) lesions has linked the presence GCs states uncontrolled hyperglycaemia diabetes mellitus type 2 patients. study purpose to find a correlation between systemic metabolic features patients GBM.Also, try correlate GCs, molecular changes, use anti-diabetic drugs on overall survival GBM Methods Electronic medical records from newly diagnosed were retrospectively reviewed extracted for demographic, clinical, metabolic, radiological pathological variables emphasis different - related features. A statistic-based comparison was made without same variables. We compared DM2 GC-GBM non-GC cohort poorly controlled (i.e., HBA1C ≥ 8.0). possible influence metformin administration OS patients, TP53 mutations investigated. Results total 220 included study. 14.5% defined as (group 1, n=32) 85.5% 2, n=188). The incidence 25% both groups. rate poorly-controlled nearly twice group 1 than (18.75% vs. 9.5%; p=0.130). group, significant differences found 1a, n=9) 2a, n=49) male gender predominance (89% 50%, p=0.073) obesity. Patients 1a more likely have weight ≥85kg (OR 6.16; 95% CI 1.3336 28.5147, p=0.0019) had higher BMI values (mean 34.1±11.42 28.7±5.44 2a respectively; OR= 1.095, 95%CI 1.053-1.207;p=0.034). Similar findings subgroup. None using insulin prior diagnosis (0% 61.10%, p=0.016). Survival analyses shown trends subgroups p53 metformin. Conclusion factors that marked resistance not at time significantly initial pathology. This novel finding may add glucose metabolism astrocytes astrocytes-associated tumors. changes tumor, under such metformin, affect prognosis subgroups.